These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34719544)

  • 1. [Elucidation for Intratumor Localization of a DDS-based Anticancer Drug and Enhancement of Its Therapeutic Effects via Improvement of the Tumor Microenvironment].
    Ando H
    Yakugaku Zasshi; 2021; 141(11):1241-1245. PubMed ID: 34719544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
    Ando H; Abu Lila AS; Tanaka M; Doi Y; Terada Y; Yagi N; Shimizu T; Okuhira K; Ishima Y; Ishida T
    Mol Pharm; 2018 Feb; 15(2):403-409. PubMed ID: 29287147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative evaluation of the intratumoral distribution of platinum in oxaliplatin-treated rectal cancer: In situ visualization of platinum via synchrotron radiation X-ray fluorescence spectrometry.
    Koba R; Fujita H; Nishibori M; Saeki K; Nagayoshi K; Sadakari Y; Nagai S; Sekizawa O; Nitta K; Manabe T; Ueki T; Ishida T; Oda Y; Nakamura M
    Int J Cancer; 2020 May; 146(9):2498-2509. PubMed ID: 31344279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.
    Shimizu T; Abu Lila AS; Nishio M; Doi Y; Ando H; Ukawa M; Ishima Y; Ishida T
    Cancer Sci; 2017 Sep; 108(9):1864-1869. PubMed ID: 28643902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
    Doi Y; Okada T; Matsumoto H; Ichihara M; Ishida T; Kiwada H
    Cancer Sci; 2010 Nov; 101(11):2470-5. PubMed ID: 20731663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
    Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
    J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma.
    Yang C; Liu HZ; Fu ZX; Lu WD
    BMC Biotechnol; 2011 Mar; 11():21. PubMed ID: 21401960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
    Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
    Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations.
    Matsuo NCA; Ando H; Doi Y; Shimizu T; Ishima Y; Ishida T
    Chem Pharm Bull (Tokyo); 2022; 70(5):351-358. PubMed ID: 35491191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
    Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.
    Doi Y; Abu Lila AS; Matsumoto H; Okada T; Shimizu T; Ishida T
    Int J Nanomedicine; 2016; 11():5573-5582. PubMed ID: 27822036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
    J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Circulating Thermosensitive Liposomes for the Targeted Drug Delivery of Oxaliplatin.
    Li Y; Xu P; He D; Xu B; Tu J; Shen Y
    Int J Nanomedicine; 2020; 15():6721-6734. PubMed ID: 32982229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
    Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
    Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day.
    Yang K; Zhao N; Zhao D; Chen D; Li Y
    Drug Des Devel Ther; 2013; 7():511-7. PubMed ID: 23818762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer.
    Bansal D; Gulbake A; Tiwari J; Jain SK
    Int J Biol Macromol; 2016 Jan; 82():687-95. PubMed ID: 26464131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
    Yang C; Liu HZ; Lu WD; Fu ZX
    Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.